Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The anticoagulated patient

R L Rauck1

  • 1Wake Forest University Medical Center, Winston-Salem, North Carolina, USA.

Regional Anesthesia
|November 1, 1996
PubMed
Summary
This summary is machine-generated.

Patients on antiplatelet or anticoagulant drugs rarely develop spinal hematomas, but these can cause severe paralysis. Individualized risk assessment is crucial for managing these patients undergoing surgery.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Conversion from standard opioid therapy to once-daily oral extended-release hydromorphone in patients with chronic cancer pain.

The Journal of international medical research·2008
Same author

Once-daily OROS hydromorphone for the management of chronic nonmalignant pain: a dose-conversion and titration study.

International journal of clinical practice·2007
Same author

An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM).

Annals of oncology : official journal of the European Society for Medical Oncology·2005
Same author

A randomized, double-blind, placebo-controlled trial of a glycine antagonist in neuropathic pain.

Neurology·2002
Same author

Paraspinal fluid extravasation from long-term epidural catheter delivery system.

Anesthesiology·1998
Same author

Chronic low back pain: new perspectives and treatment guidelines for primary care: Part II.

Managed care interface·1998
Same journal

Labor analgesia and anesthesia in a patient with spinal muscular atrophy and vocal cord paralysis.

Regional anesthesia·1998
Same journal

Unilateral spinal anesthesia: fact or fiction?

Regional anesthesia·1998
Same journal

Versatile technology: anesthetic application of an implantable pump.

Regional anesthesia·1998
Same journal

A simplified maneuver for transarterial approach to axillary block for use by a single anesthesiologist--more explanation.

Regional anesthesia·1998
Same journal

Use of the pulse oximeter for teaching axillary nerve block.

Regional anesthesia·1998
Same journal

Response to Dr. Neal's comments and to paper by Dr. Rathmell et al.

Regional anesthesia·1998
See all related articles

Area of Science:

  • Anesthesiology
  • Neurosurgery
  • Hematology

Background:

  • Increased use of antiplatelet and anticoagulant therapies in surgical patients.
  • Spinal hematomas, though rare, carry a high risk of severe neurological deficits.
  • Individualized management is essential for patients with bleeding risks.

Purpose of the Study:

  • To review the risks and management strategies for spinal hematomas in patients on antithrombotic therapy.
  • To emphasize the importance of individualized risk-benefit analysis for regional anesthesia in these patients.

Main Methods:

  • Review of current literature and clinical guidelines.
  • Discussion of factors influencing the decision for regional anesthesia versus general anesthesia.
  • Emphasis on thorough documentation and informed consent.

Related Experiment Videos

Main Results:

  • The incidence of spinal hematoma is very low, even with perioperative antithrombotic therapy.
  • Devastating neurological sequelae, including paralysis, can occur despite prompt treatment.
  • Certain high-risk groups (e.g., on fibrinolytic agents) should avoid neuraxial blocks.

Conclusions:

  • Management of patients on antithrombotic therapy requires careful, individualized assessment of bleeding risk versus procedural benefit.
  • Thorough documentation of the risk-benefit analysis and informed consent is critical.
  • Continued case reporting is vital for advancing knowledge on spinal hematomas and antithrombotic therapies.